To begin to test the efficacy of the DNA-PKcs/mTOR dual inhibitor CC-115 as a treatment for RCC, the established human RCC cell line, 786-O, was treated with gradually-increasing concentrations of CC-115 [11, 21]. This evidence concerns the gene MTOR and renal cell carcinoma.